167 related articles for article (PubMed ID: 26993602)
1. Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma.
Agarwal S; Ghosh R; Chen Z; Lakoma A; Gunaratne PH; Kim ES; Shohet JM
Oncotarget; 2016 Apr; 7(17):24018-26. PubMed ID: 26993602
[TBL] [Abstract][Full Text] [Related]
2. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
[TBL] [Abstract][Full Text] [Related]
3. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
4. PAG1 directs SRC-family kinase intracellular localization to mediate receptor tyrosine kinase-induced differentiation.
Foltz L; Palacios-Moreno J; Mayfield M; Kinch S; Dillon J; Syrenne J; Levy T; Grimes M
Mol Biol Cell; 2020 Sep; 31(20):2269-2282. PubMed ID: 32726167
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
[TBL] [Abstract][Full Text] [Related]
6. [Screening of phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1) by cDNA microarray and influence of overexpression of PAG1 on biologic behavior of human metastatic prostatic cancer cell line in vitro].
Yu WJ; Wang YW; Xie ZG; You JF; Wang JL; Cui XL; Pei F; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2010 Feb; 39(2):88-94. PubMed ID: 20388373
[TBL] [Abstract][Full Text] [Related]
7. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of PAG1/Cbp contributes to adipose-derived mesenchymal stem cells promoted tumor progression and chemoresistance in breast cancer.
Lu Y; Yang Y; Liu Y; Hao Y; Zhang Y; Hu Y; Jiang L; Gong Y; Wu K; Liu Y
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):719-727. PubMed ID: 29079189
[TBL] [Abstract][Full Text] [Related]
9. miR-205 Inhibits Neuroblastoma Growth by Targeting cAMP-Responsive Element-Binding Protein 1.
Chen S; Jin L; Nie S; Han L; Lu N; Zhou Y
Oncol Res; 2018 Apr; 26(3):445-455. PubMed ID: 28653600
[TBL] [Abstract][Full Text] [Related]
10. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
11. PAG1 promotes the inherent radioresistance of laryngeal cancer cells via activation of STAT3.
Shen L; Ke Q; Chai J; Zhang C; Qiu L; Peng F; Deng X; Luo Z
Exp Cell Res; 2018 Sep; 370(1):127-136. PubMed ID: 29913153
[TBL] [Abstract][Full Text] [Related]
12. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68.
Zhao D; Tian Y; Li P; Wang L; Xiao A; Zhang M; Shi T
Mol Med Rep; 2015 Oct; 12(4):5554-60. PubMed ID: 26136151
[TBL] [Abstract][Full Text] [Related]
14. Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.
Saeki N; Saito A; Sugaya Y; Amemiya M; Ono H; Komatsuzaki R; Yanagihara K; Sasaki H
Cancer Genomics Proteomics; 2018; 15(3):165-174. PubMed ID: 29695398
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Csk-binding protein contributes to renal cell carcinogenesis.
Feng X; Lu X; Man X; Zhou W; Jiang LQ; Knyazev P; Lei L; Huang Q; Ullrich A; Zhang Z; Chen Z
Oncogene; 2009 Sep; 28(37):3320-31. PubMed ID: 19581936
[TBL] [Abstract][Full Text] [Related]
16. [Influence of phosphoprotein associated with glycosphingolipid microdomains 1 on biologic behavior of human prostatic cancer cell line in-vitro].
Yu WJ; Wang YW; You JF; Wang JL; Cui XL; Pei F; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):615-20. PubMed ID: 21092590
[TBL] [Abstract][Full Text] [Related]
17. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell factor 1 inhibits proliferation and migration and induces apoptosis of neuroblastoma cells by inhibiting the ERK signaling pathway.
Luo G; Feng R; Sun Y; Zheng L; Wang Y; Chen Y; Wen T
Oncol Rep; 2019 Jan; 41(1):103-112. PubMed ID: 30365123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
